were investigated. The effect of 1-cyclohexyl-3-dodecyl urea (CDU), a sEH, was tested on the vasodilator effect induced by 11, 12-EET in the perfused mesenteric beds isolated from normo-glycaemic and type-1 STZ-diabetic rats.
the activation of ion channels and signalling transduction pathways. 2 It is also reported that cells can take up EETs and integrate them into phospholipids, binding to cytosolic proteins and nuclear receptors. 1 It is possible that they contribute to the pathogenesis of several disorders. 3 The conversion of EETs to dihydroxyeicosatrienoic acids (DHET)
is attained by soluble epoxide hydrolase (sEH). 1 The main EET catabolic pathway is conversion to the corresponding DHET by sEH. Moreover, it is common that EETs may have one action in the periphery and an opposite effect in the pulmonary system. Therefore, such observations raise attention about the role of EETs in pulmonary hypertension, especially in cases of hypoxia.
4
According to the definition of Hesselink, an autacoid is a modulating factor that is produced locally; it influences the function of cells and/or tissues in a limited region or position. An autacoid is produced in response to demand and is subsequently broken down in the same cells and/or tissues. Therefore, 11, 12-EET can be considered an autacoid. 5 The effect of 11, 12-EET (C 20 H 32 O 3 ) on intestinal vasculature is not well established. The mesenteric bed comprises mainly of arterioles that significantly contribute to the total peripheral resistance. Accordingly, the objective of this investigation was to examine the effect of 11, 12- EET in the rat perfused mesenteric bed. The contribution of nitric oxide and cyclo-oxygenase has been examined using inhibitors of nitric oxide synthase and cyclo-oxygenase. In addition, the participation of potassium channels in the modulation of the vasodilation response to 11, 12-EET was studied using specific potassium channel inhibitors: K 
4,5
Abnormal vascular responsiveness of the mesenteric beds from diabetic animals to 11, 12-EET would reflect vascular dysfunction induced by diabetes.
| MATERIALS AND METHODS

| Animal groups
Two groups of animals were used in this project (N=12 per group).
Group 1 included control male Sprague-Dawley (SD) rats, while Group 2 included diabetic male SD rats. Diabetes was induced by one intraperitoneal injection (55 mg/kg, body weight) of streptozotocin (STZ). [6] [7] [8] Rats were confirmed to be diabetic and approved for this investigation when fasting blood glucose levels were measured to be over 250 mg/dL. 
| Experimental procedure
Rats were anesthetized with ketamine (50mg/mL) 4weeks after mol/L) for 30 minutes. After the incubation period, the effect of 11, 12-EET, carbachol or SNP was examined in the presence of CDU.
Separate tissues were used to test the effect of different agonists.
| Effects of NO synthase and cyclo-oxygenase inhibitors on vasorelaxant responses induced by 11,
12-EET in control animals
In this experimental protocol, the effect of NG-nitro-l-arginine methyl ester (l-NAME) and indomethacin, inhibitors of nitric oxide synthase (NOS) and cyclo-oxygenase, respectively, was investigated on 11, 12-EET-induced vasodilation. 
| Influence of transient receptor potential channel V4 (TRPV4) inhibitor
This part of the study involved examining the impact of the transient
on vasorelaxant responses induced by 11, 12-EET in the mesenteric vasculature. After constructing a dose-response curve to 11, 12-EET, the mesenteric beds obtained from control animals were perfused for 30minutes with the inhibitor of TRPV4 channel, RuR (10 −6 mol/L), added to the KH solution. Thereafter, vasorelaxant responses to 11, 12-EET were examined while the inhibitor was present in the perfusing solution, as described previously.
| Drugs and chemicals
Carbachol, sodium nitroprusside (SNP), phenylephrine, l-NAME, indo- 
| Statistical analysis
Results obtained from the experiments were evaluated by applying 
| RESULTS
| Hyperglycaemia along with changes in body weight
Diabetes was induced by a single intraperitoneal injection of STZ that caused a considerable augmentation in the concentration of glucose. Hyperglycaemia persisted with the diabetic animals and was 562.68±9.64mg/dL after 4weeks of diabetes induction compared with91.0±0.55mg/dLinthenormo-glycaemicrats(P<.05). Diabetes persistentfor4weekscausedaconsiderabledecreaseinSTZ-diabetic rats body weight (257.40±1.30g) compared to control animals (310±1.87 g) (P<.05). Vasodilator responses to SNP were not changed in tissues isolated from normal or diabetic animals following incubation with CDU ( Figure 5 ). 
| 11, 12-EET-induced responses in
| Vasodilator responses to11, 12-EET in the presence of potassium channel inhibitors
In the mesenteric beds isolated from SD control male rats, 11, 12-EET 
| Influence of transient receptor potential channel V4 (TRPV4) inhibitor on 11, 12-EETinduced responses
In the perfused mesenteric beds isolated from control SD rats, 11, 12-EET-induced vasodilator responses at (0.1, 1.0, 10 nmol) were mol/L). This study showed that 11, 12-EET produced dose-dependent vasodilator response that was consistent with previous studies.
| DISCUSSION
20,21
We have found that specific inhibitors of nitric oxide synthase and cyclo-oxygenase inhibitors did not inhibit the vasodilatation due to 11, 12-EET. Results from these experiments demonstrated that 11, 12-EET is a vasodilator agent in the perfused rat mesenteric vasculature. In addition, the dilator response was independent from NO and COX, suggesting that NO/COX vasodilator pathways are not directly contributing in mediating the vasodilator responses of 11, 12-EET in this vascular bed. Moreover, Wong and Vanhoutte 22 reported that the endothelium produces several materials to regulate the basal force in the vascular smooth muscle. Endothelium-derived relaxing factor is characterized to be NO. 23 The basal force can be enhanced by producing endothelium-derived contracting factors (EDCF) from the endothelial layer. 24 It is reported that an increase in the release of EDCF can lead to abnormal function of the endothelium and that occurs in different various vascular disorders. A variety of stimuli can cause EDCF production, including agonists like acetylcholine, adenosine nucleotides or by stretch. 25 It is reported that the synthesis of cyclo-oxygenase-dependent endothelial-derived contracting factors may be affected in some disease conditions. 26 Therefore, when we blocked COX enzyme with indomethacin, there was a significant potentiation in the vasodilatation due to 11, 12-EET in the perfused vascular bed.
Endothelium-derived hyperpolarizing factor was defined pharmacologically by Campbell et al. 27 EDHF is therefore known to provoke an endothelium-dependent vasorelaxation that cannot be abolished by inhibitors of NO synthase and cyclo-oxygenase. 27 Others also reported that EDHF shows distinctive properties compared to NO and prostacyclin. For example, agonists may cause hyperpolarization while inhibitors of both cyclo-oxygenase and NO synthase are present. Following that, sodium-potassium ATPase or inward rectifying (K ir ) K channel is activated in response to potassium ions. This results in a hyperpolarizing and relaxing effect on VSMCs due to transmission of the hyperpolarizing current from endothelial cells into VSMCs.
The results of this study suggest that 11, 12-EET or blockage of its breakdown and/or metabolism may provide a valuable tool in preventing vascular dysfunction and in metabolic diseases such as diabetes.
Inhibition of sEH is a possible method to augment the protection of vascular beds through intimate EETs, which may prove to be effective in the management of many cardiovascular and metabolic problems. 
